![](/img/cover-not-exists.png)
PCN161 COST-EFFECTIVENESS OF FOLFIRI + CETUXIMAB VS. FOLFIRI + BEVACIZUMAB IN FIRST-LINE TREATMENT OF RAS WILD-TYPE (WT) METASTATIC COLORECTAL CANCER WITH LEFT-SIDED PRIMARY TUMOUR LOCATION IN ITALY: A COUNTRY ADAPTATION BASED ON THE FIRE-3 TRIAL
van Oostrum, I., Bruno, G.M., Novelli, P., Pescott, C.Volume:
22
Journal:
Value in Health
DOI:
10.1016/j.jval.2019.09.357
Date:
November, 2019
File:
PDF, 322 KB
2019